Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Up 44.4% in February

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 2,310,000 shares, a growth of 44.4% from the January 31st total of 1,600,000 shares. Based on an average daily volume of 2,460,000 shares, the short-interest ratio is presently 0.9 days.

Analyst Ratings Changes

A number of research firms have recently issued reports on ITCI. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research report on Tuesday. They issued a “hold” rating on the stock. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Finally, Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Ten research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Intra-Cellular Therapies presently has an average rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Stock Down 0.0 %

ITCI stock opened at $131.24 on Wednesday. The company has a 50-day simple moving average of $116.44 and a 200 day simple moving average of $92.52. The company has a market capitalization of $13.95 billion, a P/E ratio of -150.85 and a beta of 0.72. Intra-Cellular Therapies has a fifty-two week low of $63.30 and a fifty-two week high of $131.36.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Equities analysts anticipate that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Institutional Investors Weigh In On Intra-Cellular Therapies

Institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its position in shares of Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock valued at $1,878,000 after purchasing an additional 2,157 shares during the period. Barclays PLC grew its holdings in Intra-Cellular Therapies by 282.0% during the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after acquiring an additional 25,435 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Intra-Cellular Therapies by 31.9% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock worth $33,258,000 after acquiring an additional 109,892 shares in the last quarter. Oak Ridge Investments LLC raised its position in Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock worth $1,656,000 after acquiring an additional 8,440 shares in the last quarter. Finally, Cynosure Group LLC lifted its holdings in Intra-Cellular Therapies by 161.0% in the 3rd quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company’s stock valued at $1,057,000 after acquiring an additional 8,909 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.